Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eribulin
Drug ID BADD_D00798
Description Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Indications and Usage For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Marketing Status approved; investigational
ATC Code L01XX41
DrugBank ID DB08871
KEGG ID D08914
MeSH ID C490954
PubChem ID 11354606
TTD Drug ID D0XQ5X
NDC Product Code Not Available
UNII LR24G6354G
Synonyms eribulin | E 7389 | E-7389 | ER-086526 | ER086526 | ER 086526 | ER-86526 | Halaven | NSC 707389 | NSC707389 | NSC-707389 | B 1793 | B-1793 | B 1939 | B-1939 | eribulin mesylate | eribulin monomethanesulfonate | eribulin mesilate | eribulin (as mesylate)
Chemical Information
Molecular Formula C40H59NO11
CAS Registry Number 253128-41-5
SMILES CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O 2)OC(C9OC)CC(CN)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cystitis haemorrhagic20.03.02.0030.000336%Not Available
Deafness04.02.01.0010.000358%Not Available
Dehydration14.05.05.0010.000694%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.000280%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.000112%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000336%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000112%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysaesthesia23.03.03.077; 17.02.06.0030.000112%
Dysarthria19.19.03.001; 17.02.08.0010.000168%
Dysgeusia17.02.07.003; 07.14.03.0010.000884%
Dyspepsia07.01.02.001--
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.0060.000280%
Dyspnoea02.11.05.003; 22.02.01.004--
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000112%Not Available
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Enterocolitis07.08.03.0030.000112%
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Erythropenia01.07.02.0010.000112%Not Available
Extravasation08.01.03.0080.000683%Not Available
Eye disorder06.08.03.001--Not Available
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.0040.000112%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages